Patents Assigned to Dose Medical Corporation
-
Patent number: 11883525Abstract: The present disclosure provides compositions that enable sustained release of a small molecule tyrosine kinase inhibitor, such as axitinib from a bioerodible polyester polymer implant for the treatment of disease. The composition is especially suitable for treating ophthalmic indications, such as neovascular age related macular degeneration and diabetic macular edema, by intravitreal injection of the implant. The implant is designed to be pre-loaded into a small diameter needle and injected via self-sealing scleral needle penetration at the pars plana. Small molecule tyrosine kinase inhibitors may be released from the implants over a period of one week to three years.Type: GrantFiled: May 29, 2020Date of Patent: January 30, 2024Assignee: DOSE MEDICAL CORPORATIONInventors: Patrick Michael Hughes, James Shiah, Jack Xie, Jia-Ying Yang
-
Patent number: 11426306Abstract: Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.Type: GrantFiled: February 15, 2019Date of Patent: August 30, 2022Assignee: DOSE MEDICAL CORPORATIONInventors: David S. Haffner, Thomas W. Burns, Harold A. Heitzmann, Kenneth M. Curry
-
Patent number: 11383006Abstract: The present disclosure is directed to a composite implant for the sustained release of a therapeutic agent from a hydrogel matrix. The hydrogel matrix may be a cross-linked bioerodible polyethylene glycol (PEG) hydrogel with a therapeutic complex dispersed within the cross-linked bioerodible PEG hydrogel. The therapeutic complex may include a therapeutic agent in association with mesoporous silica particles. The composite implant is configured to be delivered to or implanted into an eye of a subject or patient. The composite implant may be used treat ocular disease in a subject or patient. Ocular diseases may be selected from at least one of neovascular age related macular degeneration (AMD), diabetic macular edema, or macular edema following retinal vein occlusion.Type: GrantFiled: August 5, 2020Date of Patent: July 12, 2022Assignee: DOSE MEDICAL CORPORATIONInventors: Patrick Michael Hughes, Ina Mustafaj
-
Patent number: 11318043Abstract: An ocular implant configured for implantation into the eye of a subject comprising an elongate outer shell (54), an internal plug (210) including a hydrogel and a drug reservoir including a drug (62) wherein the drug is configured to pass through at least a portion of the internal plug to control elution of the drug through the outer shell. The implant is made of biodegradable materials.Type: GrantFiled: April 20, 2017Date of Patent: May 3, 2022Assignee: DOSE MEDICAL CORPORATIONInventors: Harold Alexander Heitzmann, David Steven Haffner, Kenneth Martin Curry, Thomas W. Burns
-
Patent number: 11253394Abstract: Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.Type: GrantFiled: February 20, 2018Date of Patent: February 22, 2022Assignee: Dose Medical CorporationInventors: David S. Haffner, Thomas W. Burns, Harold A. Heitzmann, Kenneth M. Curry
-
Patent number: 10813789Abstract: Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.Type: GrantFiled: June 5, 2017Date of Patent: October 27, 2020Assignee: Dose Medical CorporationInventors: David S. Haffner, Kenneth M. Curry, Harold A. Heitzmann, David Applegate
-
Patent number: 10206813Abstract: Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.Type: GrantFiled: March 7, 2014Date of Patent: February 19, 2019Assignee: Dose Medical CorporationInventors: David S. Haffner, Thomas W. Burns, Harold A. Heitzmann, Kenneth M. Curry
-
Publication number: 20180193189Abstract: Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.Type: ApplicationFiled: March 7, 2014Publication date: July 12, 2018Applicant: Dose Medical CorporationInventors: David S. Haffner, Thomas W. Burns, Harold A. Heitzmann, Kenneth M. Curry
-
Patent number: 9789001Abstract: Implants and methods for treating ocular disorders are provided. One method involves introducing an implant into an anterior chamber of an eye. The implant is implanted into eye tissue adjacent the anterior chamber such that a proximal end of the implant resides in the anterior chamber following implantation. A therapeutic agent is eluted from the implant into the eye. Desirably, the release of the therapeutic agent from the implant is controlled. The controlled release of the therapeutic agent can be at a chosen rate and/or for a selected duration which can be episodic or periodic. The therapeutic agent can be an antiproliferative agent, an anti-inflammatory drug, or a compound for treating glaucoma or ocular hypertension.Type: GrantFiled: June 29, 2015Date of Patent: October 17, 2017Assignee: DOSE MEDICAL CORPORATIONInventors: Hosheng Tu, Barbara A. Niksch, David S. Haffner, Gregory T. Smedley, Olav B. Bergheim, Morteza Gharib, Richard A. Hill, Thomas W. Burns
-
Patent number: 9668915Abstract: Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.Type: GrantFiled: November 22, 2011Date of Patent: June 6, 2017Assignee: DOSE MEDICAL CORPORATIONInventors: David Haffner, Ken Curry, Harold Heitzmann, David Applegate
-
Patent number: 9636255Abstract: Devices and methods for treating intraocular pressure are disclosed. The devices include drug delivery implants for treating ocular tissue. Optionally, the devices also include shunts for draining aqueous humor from the anterior chamber to the uveoscleral outflow pathway, including the supraciliary space and the suprachoroidal space. The drug delivery implants can be implanted in ab interno or ab externo procedures.Type: GrantFiled: February 12, 2010Date of Patent: May 2, 2017Assignee: DOSE MEDICAL CORPORATIONInventors: David Haffner, Kenneth Curry
-
Patent number: 9603738Abstract: Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more, drugs and may also Include structures which allow for treatment of Increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.Type: GrantFiled: March 10, 2014Date of Patent: March 28, 2017Assignee: DOSE MEDICAL CORPORATIONInventors: David S. Haffner, Thomas W. Burns, Harold A. Heitzmann, Kenneth M. Curry
-
Patent number: 9066782Abstract: Implants and methods for treating ocular disorders are provided. One method involves introducing an implant into an anterior chamber of an eye. The implant is implanted into eye tissue adjacent the anterior chamber such that a proximal end of the implant resides in the anterior chamber following implantation. A therapeutic agent is eluted from the implant into the eye. Desirably, the release of the therapeutic agent from the implant is controlled. The controlled release of the therapeutic agent can be at a chosen rate and/or for a selected duration which can be episodic or periodic. The therapeutic agent can be an antiproliferative agent, an anti-inflammatory drug, or a compound for treating glaucoma or ocular hypertension.Type: GrantFiled: December 17, 2012Date of Patent: June 30, 2015Assignee: Dose Medical CorporationInventors: Hosheng Tu, Barbara A Niksch, David S Haffner, Gregory T Smedley, Olav B Bergheim, Morteza Gharib, Richard A. Hill, Thomas W. Burns
-
Publication number: 20140303544Abstract: Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.Type: ApplicationFiled: March 7, 2014Publication date: October 9, 2014Applicant: Dose Medical CorporationInventors: David S. Haffner, Thomas W. Burns, Harold A. Heitzmann, Kenneth M. Curry
-
Publication number: 20140012177Abstract: Implants and methods for treating ocular disorders are provided. One method involves introducing an implant into an anterior chamber of an eye. The implant is implanted into eye tissue adjacent the anterior chamber such that a proximal end of the implant resides in the anterior chamber following implantation. A therapeutic agent is eluted from the implant into the eye. Desirably, the release of the therapeutic agent from the implant is controlled. The controlled release of the therapeutic agent can be at a chosen rate and/or for a selected duration which can be episodic or periodic. The therapeutic agent can be an antiproliferative agent, an anti-inflammatory drug, or a compound for treating glaucoma or ocular hypertension.Type: ApplicationFiled: December 17, 2012Publication date: January 9, 2014Applicant: DOSE MEDICAL CORPORATIONInventor: DOSE MEDICAL CORPORATION
-
Patent number: 8348877Abstract: Implants and methods for treating ocular disorders are provided. One method involves introducing an implant into an anterior chamber of an eye such that at least a distal end of the implant is temporarily in the anterior chamber. The implant is implanted into eye tissue adjacent the anterior chamber. A therapeutic agent is eluted from the implant into at least one of the anterior chamber, a physiologic outflow pathway of the eye, and a space adjacent a choroid of the eye. The therapeutic agent can be an antiproliferative agent, an anti-inflammatory drug, or a compound for treating glaucoma or ocular hypertension. The therapeutic agent can be contained within the implant or coated on the implant.Type: GrantFiled: May 3, 2010Date of Patent: January 8, 2013Assignee: Dose Medical CorporationInventors: Hosheng Tu, Barbara Niksch, David Haffner, Gregory Smedley, Olav B Bergheim, Morteza Gharib
-
Publication number: 20120259195Abstract: The invention discloses a trabecular stent and methods for treating glaucoma. The stent may incorporate an intraocular pressure sensor comprising a compressible element that is implanted inside an anterior chamber of an eye, wherein at least one external dimension of the element correlates with intraocular pressure. In some embodiments, the sensor may be coupled to the stent. Also disclosed are methods of delivery of the stent and the sensor to the eye.Type: ApplicationFiled: March 9, 2012Publication date: October 11, 2012Applicant: Dose Medical CorporationInventors: David S. Haffner, Hosheng Tu, Morteza Gharib
-
Publication number: 20120253258Abstract: Ocular implants, delivery devices and methods for treating ocular disorders are disclosed. One method involves inserting an implant on one side of an eye. The implant has an anchor on a distal end portion and an outlet opening that is disposed proximal of the anchor. The implant is advanced across the eye to the other side of the eye. The anchor is inserted into eye tissue on the other side of the eye. A therapeutic agent is eluted using the implant.Type: ApplicationFiled: February 17, 2012Publication date: October 4, 2012Applicant: DOSE MEDICAL CORPORATIONInventors: Hosheng Tu, Jason Artof, David Haffner
-
Publication number: 20120165933Abstract: Devices and methods for treating intraocular pressure are disclosed. The devices include drug delivery implants for treating ocular tissue. Optionally, the devices also include shunts for draining aqueous humor from the anterior chamber to the uveoscleral outflow pathway, including the supraciliary space and the suprachoroidal space. The drug delivery implants can be implanted in ab interno or ab externo procedures.Type: ApplicationFiled: February 12, 2010Publication date: June 28, 2012Applicant: DOSE MEDICAL CORPORATIONInventors: David Haffner, Kenneth Curry
-
Publication number: 20120078362Abstract: Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allows for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.Type: ApplicationFiled: May 18, 2010Publication date: March 29, 2012Applicant: DOSE MEDICAL CORPORATIONInventors: David Haffner, Ken Curry, Harold Heitzmann, David Applegate